These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

850 related articles for article (PubMed ID: 30126458)

  • 21. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
    Jacobsen PL; Mahableshwarkar AR; Serenko M; Chan S; Trivedi MH
    J Clin Psychiatry; 2015 May; 76(5):575-82. PubMed ID: 26035185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
    Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
    JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Head-To-Head Comparison of Vortioxetine Versus Desvenlafaxine in Patients With Major Depressive Disorder With Partial Response to SSRI Therapy: Results of the VIVRE Study.
    McIntyre RS; Florea I; Pedersen MM; Christensen MC
    J Clin Psychiatry; 2023 May; 84(4):. PubMed ID: 37227402
    [No Abstract]   [Full Text] [Related]  

  • 26. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
    Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
    Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using non-steroidal anti-inflammatory drugs in the treatment of depression.
    Davis A; Gilhooley M; Agius M
    Psychiatr Danub; 2010 Nov; 22 Suppl 1():S49-52. PubMed ID: 21057403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.
    Findling RL; DelBello MP; Zuddas A; Emslie GJ; Ettrup A; Petersen ML; Schmidt SN; Rosen M
    J Am Acad Child Adolesc Psychiatry; 2022 Sep; 61(9):1106-1118.e2. PubMed ID: 35033635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study.
    Chen Y; Cao X; Zang W; Tan S; Ou CQ; Shen X; Gao T; Zhao L
    Trials; 2019 Jan; 20(1):34. PubMed ID: 30626424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder.
    Al-Sukhni M; Maruschak NA; McIntyre RS
    Expert Opin Drug Saf; 2015 Aug; 14(8):1291-304. PubMed ID: 26022537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study.
    Wang J; Liu XF; Feng C; Bao Q; Fu HR
    Int J Psychiatry Clin Pract; 2019 Nov; 23(4):245-250. PubMed ID: 29113521
    [No Abstract]   [Full Text] [Related]  

  • 33. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
    Llorca PM; Lançon C; Brignone M; Rive B; Salah S; Ereshefsky L; Francois C
    Curr Med Res Opin; 2014 Dec; 30(12):2589-606. PubMed ID: 25249164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study.
    McDaniel BT; Cornet V; Carroll J; Chrones L; Chudzik J; Cochran J; Guha S; Lawrence DF; McCue M; Sarkey S; Lorenz B; Fawver J
    BMC Psychiatry; 2023 Dec; 23(1):938. PubMed ID: 38093196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
    Baldwin DS; Florea I; Jacobsen PL; Zhong W; Nomikos GG
    J Affect Disord; 2016 Dec; 206():140-150. PubMed ID: 27474960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
    Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A
    CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD).
    Chokka P; Bougie J; Rampakakis E; Proulx J
    CNS Spectr; 2019 Jun; 24(3):338-347. PubMed ID: 29792585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder.
    Liebowitz MR; Careri J; Blatt K; Draine A; Morita J; Moran M; Hanover R
    Depress Anxiety; 2017 Dec; 34(12):1164-1172. PubMed ID: 29166552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolerability and efficacy of vortioxetine versus SSRIs in elderly with major depression. Study protocol of the VESPA study: a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial.
    Ostuzzi G; Gastaldon C; Barbato A; D'Avanzo B; Tettamanti M; Monti I; Aguglia A; Aguglia E; Alessi MC; Amore M; Bartoli F; Biondi M; Bortolaso P; Callegari C; Carrà G; Caruso R; Cavallotti S; Crocamo C; D'Agostino A; De Fazio P; Di Natale C; Giusti L; Grassi L; Martinotti G; Nosé M; Papola D; Purgato M; Rodolico A; Roncone R; Tarsitani L; Turrini G; Zanini E; Amaddeo F; Ruggeri M; Barbui C
    Trials; 2020 Aug; 21(1):695. PubMed ID: 32746941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using early changes in cold cognition to predict response to vortioxetine in major depressive disorder.
    Park C; Zuckerman H; Subramaniapillai M; Mansur RB; Rosenblat JD; Cao B; Iacobucci M; Lee Y; Levitan R; Blumberger DM; McIntyre RS
    Psychiatry Res; 2020 Feb; 284():112767. PubMed ID: 31978627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.